Alternatives to Brenus Pharma

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Biomica is developing a novel microbiome-based platform for the treatment of cancer.

Develops a platform for individual drug customization using aptamers for cancer treatment.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

A global leader in clinical pharmacology and bioanalytical sciences.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Developing novel immunotherapies and diagnostics for cancer.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

A biotechnology company developing genetic therapies for rare disorders.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

Developing TCR-mimetic antibody therapies to treat cancer by targeting peptide-loaded major histocompatibility complexes.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

Developing oral small molecule medicines for immunological and chronic diseases.

Pioneering vision restoration therapies for severe retinal degenerations.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

Developing first-in-class oral therapy for BK polyomavirus infections.

A biotechnology company focused on oncology drug discovery.

Immunotherapy company targeting oncology and autoimmune diseases.

Clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies.

Developing novel male contraceptives.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

Advancing targeted alpha therapies.

South Korean biopharmaceutical company developing novel biologics for cancer and rare diseases.

Developing a new histotripsy therapeutic platform for cancer treatment.

A biopharmaceutical company focused on drug discovery and development.

Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.

Developing a next-generation, off-the-shelf, in vivo engineered monocyte immunotherapy platform for solid tumors.

Biopharmaceutical company developing T-cell therapies for solid tumor cancers.

Biopharmaceutical company developing innovative therapies for sepsis and intensive care.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

Clinical-stage biopharmaceutical company developing treatments for brain and peripheral disorders involving the CB1 receptor.

Biopharmaceutical company developing best-in-class medicines for autoimmune and rare diseases, with a focus on thyroid eye disease.

Accelerating medicine for the people who need it, prescribe it, and create it.

Clinical-stage biotech company developing transformative cytokine therapies.

Discovering and developing first-in-class antibody therapeutics by identifying protective antibodies from disease-resilient individuals.

Developing novel therapeutics for inflammatory and hypoxic diseases.

Pioneering next-generation bispecific ADCs for cancer treatment.

Venture philanthropy organization accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD).

Biotechnology company defining membrane protein spatial relationships to create novel therapeutics for cancer and autoimmune diseases.

A clinical-stage dermatology company developing novel therapies for inflammatory skin diseases.